Stock screener

ICCC

Conviction 80HealthcareScan · Fri, Jun 26, 2026
ICCC$9.74-1.52%
ResistanceSupportVol 14Insider buy
63 bars
Vol MA14 24.02K
Mar 27Apr 15May 4May 20Jun 9Jun 26
IMMUCELL CORP /DE/IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCESwww.immucell.com ↗
Price9.74
Change-1.52%
Gap-0.40%
Rel volume0.63×
Avg volume23.02K
Avg $ vol224.17K
SMA 209.73
SMA 509.17
SMA 2006.93
Price vs 50+6.20%
Price vs 200+40.62%
MA stackbullish
50/200 cross—
Supertrendup · 9.10
RSI (14)54
MACD hist-0.04
MACD cross—
Stoch %K / %D54 / 62
ADX (14)20
+DI / −DI21 / 18
RSI divergenceBearish
MACD divergence—
ATR %+4.03%
ADR %3.98%
52w high10.63
52w low4.56
From 52w high-8.37%
Above 52w low+113.60%
New 52w highNo
SqueezeOn · 2d
Bollinger width8.22%
%B0.51
Donchian pos40.16%
Donchian high10.47
Donchian low9.25
AVWAP (52w high)9.87
vs AVWAP high-1.31%
AVWAP (52w low)7.46
vs AVWAP low+30.53%
OBV trendUp
Chaikin MF (20)0.01
Today vs 20d0.63×
Avg vol (14d)24.02K
Avg vol (20d)23.02K
Avg $ vol (20d)224.17K
Market cap—
RS 3m (vs SPY)+41.78%
RS 6m (vs SPY)+60.40%
RS line new highNo
Trend template8/8
Technical rank78.1
1 week+2.63%
1 month-8.37%
3 months+49.16%
6 months+67.35%
1 year+58.63%
YTD+64.53%
P/E-86.33
P/B3.08
P/S3.25
P/FCF73.31
EPS-0.1200
Div yield—
ROE-3.57%
ROA-2.36%
Debt/Eq0.30
Current4.82
EV/EBITDA20.68
Gross margin41.40%
Net margin-3.76%
Rev growth4.34%
EPS growth51.78%
Price target—
Target upside—
Analyst rating—
Institutional—
Ent. value91.68M
Revenue10.36M
Net income1.94M
Gross profit4.66M
Free cash flow1.22M
IndustryIN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
ExchangeNasdaq
Shares out9.05M
Employees73
ListedWed, Jul 8, 1987
Free float—
Float %—
Short interest—
Days to cover—
Short volume—
Squeeze score—
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeA
Conviction80 / 100
Pattern quality—
Tech rank78.1 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance10.50
Support8.12
Days since event—
Candle confirm—
News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ICCC

All disclosures →
No recent disclosed trades by Congress in ICCC. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ICCC · 10 buys

InsiderSideShares
te Boekhorst Paul Francis Olivier
President and CEO · Common Stock, par value $.01 per share · 2026-06-18
Buy8K
Turner Kathy V
Director · Non Qualified Stock Options (Right to buy) · 2026-04-15
Grant17.9K
Tomsche David Scott
Director · Non Qualified Stock Options (Right to buy) · 2026-04-15
Grant11.93K
Basse Gloria F
Director · Non Qualified Stock Options (Right to buy) · 2026-04-15
Grant11.93K
Wainman Paul R
Director · Non Qualified Stock Options (Right to buy) · 2026-04-15
Grant11.93K
Wainman Paul R
Director · Non Qualified Stock Options (Right to buy) · 2025-04-16
Grant10K
Rosgen Steven T.
Director · Non Qualified Stock Options (Right to buy) · 2025-04-16
Grant10K
Basse Gloria F
Director · Non Qualified Stock Options (Right to buy) · 2025-04-16
Grant10K
Tomsche David Scott
Director · Non Qualified Stock Options (Right to buy) · 2025-04-16
Grant10K
Brockmann Bobbi Jo
VP of Sales and Marketing · Incentive Stock Options (Right to buy) · 2025-04-16
Grant5K

SEC filings

EDGAR filings in ICCC · 2 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.